Article
Maxim Pharmaceuticals has announced that advanced metastatic melanoma patients treated with a combination of Ceplene and Interleukin-2 (IL-2) showed improved survival rates in a phase 3 trial, according to a Business Wire report.
Exploring the Effects of Masks on Skin Physiology
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Clinical Pearls for Vitiligo and Pigmentation Complexities: Part 3
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Which Tax Treatment Is Best for Your Dermatology Practice?
Facing Challenges in Pediatric Plaque Psoriasis